W

Wash U

Academic research and entrepreneurial institution

Police Captain Patrol Division

Full-TimeUpdated
$84.2k - $148.5k/yr
Expert
Bachelor's, Master's
St. Louis, MO, USA
In PersonWork is performed in office, vehicle, and outdoor settings; schedules may include nights, weekends, and holidays.
Security & Protective ServicesSecurity Guarding & Patrol

About the job

Requirements
  • A bachelor's degree in criminal justice, public administration, or a related field, or an equivalent combination of education and progressively responsible law enforcement experience.
  • Ten years of sworn law enforcement experience, including two years of supervisory experience at the rank of Lieutenant or higher.
  • Demonstrated experience directing patrol operations, managing schedules and overtime, and supervising supervisors.
  • A current Missouri POST Class A Peace Officer License, or the ability to obtain it within the timeframe required by the department.
  • Completion of NIMS/ICS courses IS-100, IS-200, IS-700, and IS-800, or completion within six months of appointment.
  • A driver's license and good driving record are required.
  • Must meet department physical, firearms, and use-of-force qualification standards.
  • Must successfully complete a comprehensive background investigation, psychological evaluation, and medical examination.
Responsibilities
  • Direct all patrol functions, ensuring continuous and effective police coverage of university campuses and properties across all shifts.
  • Establish division goals, deployment strategies, and operational priorities in alignment with the Chief's direction and department strategic plan.
  • Set and communicate daily patrol expectations for each platoon, including proactive and visible patrol of campus areas, building and property checks, community contacts, and response standards, and ensure Lieutenants and Sergeants hold officers accountable to them.
  • Review daily activity, incident reports, and crime data in partnership with the Crime/Data Analyst to identify trends and adjust patrol deployment.
  • Ensure patrol response, calls for service, and use-of-force practices meet department policy, legal requirements, and best practices in campus policing.
  • Serve as incident commander or command-level resource for critical incidents, major emergencies, and significant events; participate in the command on-call rotation.
  • Supervise, mentor, and evaluate four Police Lieutenants, holding them accountable for the performance and conduct of their platoons and assignments.
  • Oversee division performance management, including evaluations, coaching, corrective action, and recognition.
  • Review and investigate or assign complaints and internal inquiries involving patrol personnel; recommend discipline to the Chief of Police.
  • Participate in recruitment, interviewing, selection, promotion, and Field Training Officer program oversight for patrol personnel.
  • Identify training needs and coordinate with the Training Sergeant to ensure patrol personnel maintain required certifications and skills.
  • Build leadership bench strength through succession planning and professional development of Lieutenants and Sergeants.
  • Oversee Special Events operations, including security planning, staffing, and after-action review for commencement, athletics, concerts, visiting dignitaries, and other university events.
  • Direct threat and risk assessments for special events, evaluating event size, location, attendees, intelligence information, and known risks to determine staffing levels, security measures, and contingency plans, in coordination with Emergency Management, Event Services, and outside agencies as needed.
  • Oversee the Comfort Dog Program and its role in community engagement, wellness outreach, and post-incident support.
  • Represent WASHU PD on the university CARE Team, attend the weekly Monday meeting, and keep the team informed on student-involved mental health and wellness cases handled by patrol.
  • Promote community-oriented policing, relationship-building, and visible engagement with students, faculty, staff, and neighbors.
  • Represent WASHU PD at university committees, community meetings, and campus events as assigned.
  • Manage patrol staffing levels, shift schedules, minimum staffing, leave, and overtime to control costs while maintaining service levels.
  • Develop and monitor the Patrol Division's portion of the department budget; make recommendations on staffing, equipment, and vehicle needs.
  • Develop, review, and recommend updates to patrol policies, general orders, and standard operating procedures.
  • Ensure the Patrol Division meets CALEA accreditation standards and support the department's CALEA Manager with proofs of compliance, audits, and assessments.
  • Prepare division reports, statistics, and briefings for the Chief of Police and university leadership.
  • Coordinate with Dispatch, the Detective Bureau, Training, and Executive Protection to ensure seamless operations across WASHU PD.
  • Maintain working relationships and mutual-aid coordination with neighboring law enforcement and emergency response agencies.
  • Participate in university emergency management planning, exercises, and response.
  • Coordinate and support training for university partners on safety topics such as active threat response, in partnership with the Training Sergeant and Emergency Management.
  • Perform other duties as assigned by the Chief of Police, including acting in the Chief's absence when designated.
Desired Qualifications
  • A master's degree in criminal justice, public administration, leadership, or a related field.
  • Graduation from a recognized command-level leadership program, such as the FBI National Academy, Northwestern University School of Police Staff and Command, or FBI-LEEDA.
  • Experience in campus or university policing.
  • Experience with CALEA or IACLEA accreditation.
  • Completion of ICS-300 and ICS-400.
  • Experience planning and commanding large-scale special events.

About the company

Wash U translates academic research into practical technologies and programs that address global challenges. The institution supports scholars through grants and partnerships to move discoveries from the lab into the public sector via entrepreneurship and technology transfer. Unlike many traditional research institutions, Wash U emphasizes a high level of financial transparency and leverages a historical connection to Nobel Laureates to foster a collaborative environment. Its goal is to use these shared visions and research initiatives to create a more equitable future and provide tangible benefits to society.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

1853

Simplify Jobs

Simplify's Take

What believers are saying

  • Oct. 1, 2026: WashU won a $4 million DARPA grant for fuel injectors.
  • 2026: Bristol Myers Squibb partnership funds neurosciences fellows and translational programs.
  • Aug. 21, 2026: WashU Medicine's FDA-cleared Alzheimer blood test expands diagnostics revenue.

What critics are saying

  • Sept. 30, 2025: WashU cut 316 staff and 198 vacancies, showing operating stress.
  • Aug. 12, 2026 EEOC sued WashU over race-separated DEI training and retaliation.
  • Federal grant cuts can hollow out WashU Medicine's NIH engine and faculty pipeline.

What makes Wash U unique

  • WashU Medicine and BJC Health named Philip R.O. Payne chief health AI officer in 2026.
  • WashU startups raised $1.7 billion in 2025, proving translational commercialization scale.
  • WashU's February 2026 acquisition of St. Louis College of Pharmacy adds a 10th school.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Paid Vacation
  • 401(k) Company Match
  • Wellness Program
  • Mental Health Support
  • Parental Leave
  • Family Planning Benefits

Company News

CMT
Oct 22nd, 2026
College Transit Challenge kicks off Nov. 5 with Mascot Meetup.

College Transit Challenge kicks off Nov. 5 with Mascot Meetup. Travis Wood October 22, 2026 Five Area Colleges and Universities to Compete in Three-Day College Transit Challenge Five area colleges and universities are preparing to face off in the 2026 College Transit Challenge, a three-day, region-wide competition designed to show students and campus communities just how far public transit can take them. The challenge runs Thursday, Nov. 5, through Saturday, Nov. 7, and is hosted by Citizens for Modern Transit in partnership with the St. Clair County Transit District and Metro Transit. Mascot Meetup Kickoff Event - Thursday, Nov. 5 The competition begins with a Mascot Meetup at 3 p.m. on Thursday, Nov. 5, at the Grand MetroLink Station. Representatives and mascots from all five institutions will gather with students and regional transit partners for remarks about the importance of transit access and the Metro U-Pass, followed by a group photo and a MetroLink ride to a kickoff celebration at Cobblestone STL on Laclede's Landing. Bonus-point scavenger hunt missions will be revealed at the event, featuring food, drinks, goodie bags and prizes. Saint Louis University, WashU, the University of Missouri-St. Louis, Southwestern Illinois College and St. Louis Community College will compete for school bragging rights. Students, faculty, staff, alumni and supporters can register at www.CollegeTransitChallenge.com under their school and earn points by riding MetroLink and MetroBus, visiting destinations throughout the region, completing scavenger hunt-style missions and posting about their experience. "This year's expanded, three-day challenge gives participants more ways to ride, explore and compete on their own schedules," said Kimberly Cella, CEO of Citizens for Modern Transit. "Whether they take one 30-minute trip or spend all three days completing missions with friends, every ride and every point will help their school." Earn Points for Your School Registered participants will receive text messages with challenge updates. Transit trips will be tracked by text, and the online leaderboard will be updated daily. The winning school will be announced Monday, Nov. 9. Points can be earned by: * Registering and tracking MetroLink and MetroBus trips by text * Attending the kickoff event on Nov. 5 * Completing scavenger hunt-style missions * Posting about their transit experience during the challenge Possible scavenger hunt destinations include the Gateway Arch, Forest Park, the Delmar Loop, Downtown Belleville, City Foundry STL, St. Louis Union Station, Busch Stadium, Enterprise Center and Metro-accessible trails and greenways, including the MetroBikeLink. Location-specific questions or photo requirements will be used to verify completed missions. Participants can take part for 30 minutes or all three days, alone or with friends, before, between or after classes, and from anywhere on the Metro Transit system. Registered participants also can receive a "Public Transit" T-shirt in a color specific to their school, picked up on campus or at the mascot meetup on November 5, while supplies last. "Public transit connects these campuses to jobs, entertainment, parks, cultural destinations and one another," said Ken Sharkey, managing director of St. Clair County Transit District. "The College Transit Challenge makes that connection tangible and gives campus communities a fun reason to discover new places without a car." Students and staff who have not yet obtained a Metro U-Pass should check with their college or university about campus distribution. Additional challenge and point information, registration instructions and school-specific Metro U-Pass details are available at www.CollegeTransitChallenge.com.

Washington University in St. Louis
Oct 16th, 2026
Prize supports hunt for broad-spectrum antivirals.

Prize supports hunt for broad-spectrum antivirals. October 16, 2026 Researchers at WashU Medicine led by Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor in the John T. Milliken Department of Medicine, received a $2.5 million SMART Antiviral Prize to support their search for the first broad-spectrum antivirals to treat chikungunya and related viruses. The prize is part of a multistage competition run by the federal Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. Diamond's group is one of nine winning Concept Stage teams selected to identify promising antiviral candidates. Alphaviruses in the Togaviridae family - including chikungunya, which causes disabling joint pain, and equine encephalitis viruses, which can cause lasting brain damage - are spread by mosquitoes and have sickened millions of people worldwide, including in the U.S. No antiviral drug is approved to treat them. Diamond's team aims to change that by targeting the enzyme these viruses use to copy their own genetic material. Because this enzyme doesn't vary much from one alphavirus to the next, a compound that targets it could work against many alphaviruses at once.

Washington University in St. Louis
Oct 16th, 2026
Leath earns award from brain science professionals.

Leath earns award from brain science professionals. WashU's Seanna Leath, an associate professor of psychological and brain sciences in Arts & Sciences, has received the Kellina Craig-Henderson Early to Mid-Career Award for Inclusivity, Diversity, Equity and Accessibility (IDEA) from the Federation of Associations in the Behavioral and Brain Sciences (FABBS). Leath is an applied developmental psychologist and community-engaged scholar whose research examines how cultural, social and structural contexts shape the health of Black youth, families and communities. The award is given to a mid-career scholar "who has made a significant impact on the promotion and advancement of IDEA principles within the fields of the behavioral and brain sciences and for our broader scientific community," according to FABBS.

Washington University School of Medicine in St. Louis
Oct 14th, 2026
Osteoarthritis therapy study advances with $17 million from ARPA-H.

Osteoarthritis therapy study advances with $17 million from ARPA-H. Funding will support collaboration to move single-injection treatment to reverse joint damage into clinical trials A WashU Medicine project to develop an injectable treatment to reverse tissue damage in osteoarthritis has received $17 million in phase 2 funding from ARPA-H. In brief. * WashU Medicine has received $17 million from ARPA-H to develop an injectable osteoarthritis treatment. * The nanoparticle-based therapy regenerates damaged joint tissue. * In collaboration with CRISPR Therapeutics and SynGenix, the team is preparing the treatment for clinical trials, set to begin in 18 months. A project to develop a treatment that could reverse osteoarthritic tissue damage, led by researchers at Washington University School of Medicine in St. Louis, has received $17 million from the federal Advanced Research Projects Agency for Health (ARPA-H). The funding marks the second phase of a groundbreaking effort to develop a once-a-year injection treatment for a condition that affects an estimated 33 million people in the United States. The project is co-led by Farshid Guilak, PhD, the Mildred B. Simon Professor of Orthopedic Surgery at WashU Medicine and Director of Research for Shriners Children's St. Louis, and Christine T. N. Pham, MD, the Guy and Ella Mae Magness Professor of Medicine and director of the Division of Rheumatology at WashU Medicine. This next allocation of funding in phase 2.1 will support a collaboration with CRISPR Therapeutics and SynGenix, a WashU startup founded by Guilak and Pham commercializing the therapeutic technology. This partnership will complete the necessary testing and commercial development of the treatment, which was designed and tested by the WashU Medicine team in the first phase of the project. Clinical trials are scheduled to begin in 18 months. Osteoarthritis is a degenerative joint disease that can cause severe pain and limited mobility, but there are no disease-modifying drugs available for this condition. "The only nonsurgical treatments currently available for osteoarthritis are for pain relief, which does not address the underlying condition," Guilak said. "Osteoarthritis is probably the leading cause of disability for which there are no treatments that address the disease process. Our approach could allow patients to return to an active life, possibly with one injection a year, rather than having to take daily medications only to mask the pain." ARPA-H was established in 2022 as an agency within the U.S. Department of Health and Human Services to accelerate the development of high-impact solutions for health problems of this scale. Phase 1 of Guilak and Pham's work began in 2024 under the agency's Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program. "We are thrilled to announce the successful transition of Washington University in St. Louis to Phase 2.1 of NITRO," said ARPA-H NITRO Program Manager Ross Uhrich, DMD. "Their smart cell technology is a single-injection, genetically targeted therapy designed to activate only in the diseased joint, driving cartilage regeneration while suppressing the inflammatory signaling that fuels degeneration. This regenerative therapeutic is a valuable and unique asset within the NITRO portfolio that further enables us to eradicate osteoarthritis." Osteoarthritis treatment from nanoparticles. The second phase of funding was contingent on the team meeting its phase 1 milestones, by demonstrating in animal models that their treatment could regenerate osteoarthritis damage without any surgical intervention. The treatment Guilak and Pham developed relies on a "smart cell" approach. Working with Xiaoxia Cui, PhD, an associate professor of genetics and director of the Genome Engineering & Stem Cell Center at WashU Medicine, the team engineered genetic codes delivered directly into the knee joint via nanoparticles. Once internalized in joint tissue cells, these constructs can sense and respond to osteoarthritis cues such as inflammatory signals or excessive mechanical loading, which are the physical forces acting on the joint. Upon activation by the osteoarthritis cues, the engineered genetic codes instruct local cells in the joint to produce proteins that promote tissue repair and growth. Crucially, protein production ceases automatically once underlying disease signals subside, preventing excessive production of the biologic drug. "In animal models, we were able to restore a joint with severe osteoarthritis to near-baseline levels - almost 100% recovery," Pham said. "As a clinician, being part of something that could offer new treatment options for tens of millions of people is very exciting." Phase 1 was a university-spanning effort that included Lori Setton, PhD, the Lucy and Stanley Lopata Distinguished Professor and chair of the Department of Biomedical Engineering in WashU McKelvey Engineering; and Erik Herzog, PhD, the Viktor Hamburger Distinguished Professor in Arts & Sciences. In addition to achieving specific scientific milestones during phase 1, the WashU team conducted extensive community outreach in alignment with ARPA-H NITRO Program's mandate to make treatments accessible to disproportionately affected populations such as Native Americans, who have higher rates of osteoarthritis than the U.S. average. Partnering with Tobeya Ibitayo, an engagement officer with the St. Louis Integrated Health Network, the team conducted educational outreach to foster trust and encourage acceptance of this novel therapy across diverse communities. "The response was overwhelmingly positive - many people we spoke to in the community are quite excited," said Pham. "Even now I receive emails from people asking where and when they can sign up." Note: The osteoarthritis treatment described in this article is still in development and is not currently available to patients or open for clinical trial enrollment. Clinical trials are not expected to begin for at least 18 months and timelines may change. Patients interested in future participation are encouraged to monitor ClinicalTrials.gov for updates as more information becomes available.

Washington University in St. Louis
Oct 14th, 2026
Kubanek receives One Mind Rising Star Award.

Kubanek receives One Mind Rising Star Award. October 14, 2026 Jan Kubanek, an associate professor of psychiatry at WashU Medicine, received the 2026 One Mind Rising Star Award to develop a noninvasive, precision ultrasound tool that can selectively modulate areas deep within the brain associated with depression. The three-year $300,000 grant is awarded by One Mind, a global nonprofit that invests in mental health research. Kubanek is one of five early-career scientists selected this year. Major depression is a leading cause of disability worldwide, affecting nearly 300 million people, and about one in three patients do not respond to existing treatments. Therapies that alter the activity of networks of brain cells hold promise, but progress has been slowed by an incomplete understanding of which networks drive the disorder.